The use of antimicrobial drugs in preterm newborn: the experience of creating the formulary

A serious problem of treatment of infectious disease in preterm infants is the lack of sufficient information on pharmacokinetics of antibiotics in this group of patients. This is due to the insufficient number of clinical trials with premature babies, so in practice is difficult for doctor to choos...

Full description

Saved in:
Bibliographic Details
Main Authors: M. A. Ivzhits (Author), S. K. Zyryanov (Author), E. A. Ushkalova (Author), G. V. Rodoman (Author), S. I. Zhogin (Author), O. A. Babak (Author), O. I. Milyeva (Author), S. V. Dumova (Author)
Format: Book
Published: Izdatelstvo OKI, 2018-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_5ec2a35880d44b4a8bfe61f068b4b3a0
042 |a dc 
100 1 0 |a M. A. Ivzhits  |e author 
700 1 0 |a S. K. Zyryanov  |e author 
700 1 0 |a E. A. Ushkalova  |e author 
700 1 0 |a G. V. Rodoman  |e author 
700 1 0 |a S. I. Zhogin  |e author 
700 1 0 |a O. A. Babak  |e author 
700 1 0 |a O. I. Milyeva  |e author 
700 1 0 |a S. V. Dumova  |e author 
245 0 0 |a The use of antimicrobial drugs in preterm newborn: the experience of creating the formulary 
260 |b Izdatelstvo OKI,   |c 2018-05-01T00:00:00Z. 
500 |a 2588-0519 
500 |a 2618-8473 
520 |a A serious problem of treatment of infectious disease in preterm infants is the lack of sufficient information on pharmacokinetics of antibiotics in this group of patients. This is due to the insufficient number of clinical trials with premature babies, so in practice is difficult for doctor to choose appropriate antibiotic dose and frequency of dosing him. We have summed up the experience of the American pediatric form NEOFAX, British pediatric form, some clinical trials results and selected the optimal dosing regimen of antibacterial drugs based on gestational and post-conceptual age. This will contribute to safety and efficiency in the treatment of infectious diseases in premature infants caused primarily problematic nosocomial pathogens, such as Acinetobacter spp., Klebsiella pneumonia, Pseudomonas aeruginosa, MRSA, and reduce the risk of adverse drug reactions. 
546 |a RU 
690 |a недоношенные новорожденные 
690 |a антибиотики 
690 |a резистентность 
690 |a фармакокинетика 
690 |a формуляр 
690 |a preterm infants 
690 |a antibiotics 
690 |a resistanœ 
690 |a pharmacokinetics 
690 |a formulary 
690 |a Medical technology 
690 |a R855-855.5 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Качественная клиническая практика, Vol 0, Iss 3, Pp 56-65 (2018) 
787 0 |n https://www.clinvest.ru/jour/article/view/58 
787 0 |n https://doaj.org/toc/2588-0519 
787 0 |n https://doaj.org/toc/2618-8473 
856 4 1 |u https://doaj.org/article/5ec2a35880d44b4a8bfe61f068b4b3a0  |z Connect to this object online.